Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles ...

Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...

Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...

Gladstone Institutional Advisory LLC lifted its position in Veru Inc. (NASDAQ:VERU – Free Report) by 52.7% in the 4th quarter, according to the company in its most recent filing with the Securities ...